Tradestie Institutional Equity Comparison Engine

ICCC vs CSBR โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ICCC Overall Edge

ICCC Captures Institutional Edge (2โ€“1 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Immucell Corp (ICCC) driven by superior Growth & Margin, Momentum & Technical while CSBR counters with relative strength in Valuation. Fundamentally, ICCC trades at N/M Forward P/E with 15.2% operating margin (+11.5% YoY revenue) versus CSBR at 46.8x Forward P/E and -1.5% operating margin (+8.8% YoY). In options structure, ICCC sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against CSBR sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner CSBR
ICCC N/M vs CSBR 46.8x Fwd P/E
Growth & Margin Winner ICCC
Op Margin 15.2% vs -1.5% ยท YoY +11.5% vs +8.8%
Momentum & Technical Winner ICCC
1Y +88.8% vs -31.9% ยท 52W Pos 91% vs 4%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
ICCC NASDAQ
Immucell Corp
In Vitro & In Vivo Diagnostic Substances
$11.42
+6.23% 1D
Market Cap $97.7M
1M Return +6.23%
1Y Return +88.76%
Forward P/E N/M
Unified AI Score
43.8 / 100 HOLD
Tech 15.0 Fund 48.0 Flow 50.0 Mom 50.0
CSBR NASDAQ
Champions Oncology, Inc.
Biological Products, (No Disgnostic Substances)
$4.68
-0.53% 1D
Market Cap $65.5M
1M Return -0.43%
1Y Return -31.88%
Forward P/E 46.8x
Unified AI Score
44.4 / 100 HOLD
Tech 46.0 Fund 49.0 Flow 50.0 Mom 54.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ICCC +88.76% CSBR -31.88% Spread: +120.93 pp (ICCC Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ICCC TTM Op. Margin: 15.2% CSBR TTM Op. Margin: -1.5%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ICCC vs CSBR. Trailing 12-month operating profitability (ICCC 15.2% vs CSBR -1.5%) and valuation multiples (ICCC N/M vs CSBR 46.8x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ICCC (6) vs CSBR (4)
Institutional Metric ICCC CSBR Criterion Row Winner
Market Capitalization Scale $97.7M $65.5M Larger Scale ICCC
Trailing P/E Ratio Valuation 56.6x 22.9x Lower Multiple CSBR
Forward P/E Ratio Valuation N/M 46.8x Lower Multiple CSBR
Revenue Growth (YoY) Growth +11.5% +8.8% Higher Growth ICCC
Operating Margin (TTM) Profitability 15.2% -1.5% Higher Margin ICCC
Net Profit Margin Profitability 2.6% -1.9% Higher Margin ICCC
Return on Equity (ROE) Capital Efficiency 2.6% -28.4% Higher ROE ICCC
52-Week Range Position Momentum 91% ($5โ€“$12) 4% ($5โ€“$8) Stronger Trend ICCC
Beta / 30D Volatility Risk Regime 0.24ฮฒ ยท 46% Vol 0.36ฮฒ ยท 24% Vol Lower Realized Risk CSBR
Unified Institutional Score Composite Signal 43.8 / 100 (HOLD) 44.4 / 100 (HOLD) Higher Composite CSBR

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ICCC vs CSBR Buy Guide
ICCC UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live ICCC Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CSBR UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CSBR Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ICCC nor CSBR registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.